Xacrel is under clinical development by Cinnagen and currently in Phase III for Relapsing Remitting Multiple Sclerosis (RRMS). According to GlobalData, Phase III drugs for Relapsing Remitting Multiple Sclerosis (RRMS) have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Xacrel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ocrelizumab biosimilar (xacrel) is under development for the treatment of relapsing remitting multiple sclerosis (RRMS). It is administered through the intravenous route. The drug candidate acts by targeting CD20.
Cinnagen is a biotechnology products provider that markets various molecular biology, biopharmaceuticals and diagnostic products. The company provides services such as technology transfer, export and market development programs. It offers market development programs such as out-licensing, in-licensing, supply and distribution; agency, technology transfer, research and development partnering, joint-venture, contract manufacturing, and acquisitions and investment programs, among others. CinnaGen provides biosimilars, peptide-based therapeutics, therapeutic enzymes, monoclonal antibodies and recombinant proteins, among others. The company exports products across Asian, African and Latin American countries. CinnaGen is headquartered in Tehran, Iran.
For a complete picture of Xacrel’s drug-specific PTSR and LoA scores, buy the report here.